TABLE OF CONTENTS

Volume I		Tab 300: Federal Trade Commission	
How to Use This Service		Executive Summary	
		FTC Regulation of PBMs	
Table of Contents, Current Con-	tents	Definitions of Labeling and Advertising	¶302
Newsletters		FTC's Organizational Structure for Regulating	02
ide Woletter 5		Advertising and Promotion	¶320
Tab 100: Overview: Advertising a	and	Relationship Between FTC and FDA	¶330
Promotion Regulation		FTC-FDA Memorandum of Understanding	¶331
Executive Summary	¶100	Jurisdiction Over Prescription Drug Advertising.	
FDA's Authority Over Advertising and Promot		FTC's Enforcement Activities	
Federal Food, Drug and Cosmetic Act	- " "	Procedures for Reaching Decisions	
(FD&C Act) and Amendments	¶111	Consent Orders and Other Actions	¶342
Public Health Service Act (PHS Act)			
FDA's Regulation Under the FD&C Act and		Tab 400: Prescription Drugs	
the PHS Act	¶113	Executive Summary	¶400
Patient Protection and Affordable Care Act	¶114	Summary of Requirements	¶401
External Influences on FDA Activity	¶120	Definitions of Label, Labeling, Advertisements	
U.S. Congress	¶121	General Policies for Promoting Prescription	
Competitors' Complaints		Drugs	¶41(
Office of Inspector General	¶123	Routine Submission of Promotional	
Consumer and Industry Advocacy	¶124	Materials to CDER	
States	¶125	Preclearance of Promotional Materials	¶412
FTC's Authority Over Advertising of FDA-		Fair Balance	
regulated Products	¶130	Use of Brief Summary	¶414
Applicable Definitions		Reminder and Other Advertisements Exempt	
Guidelines of Professional Organizations		from the Brief Summary Requirement	
ACCME Standards		Product Name and Placement	
ACP-ASIM Guidelines		Unapproved Legacy and Grandfathered Drugs	
AMA Guidelines		Specific Claims for Prescription Drugs	¶420
AAMC Guidelines		Claims About Unapproved Products and New	
Continuing Medical Education Policy		Uses for Approved Products	
Historical Context		Accelerated Approvals and Surrogate Markers.	
Final Guidance Provisions		Off-label Claims	
First Amendment Issues and Cases	¶170	Comparative and Superiority Claims	
		Pharmacoeconomic and Quality-of-life Claims	
Tab 200: FDA's Advertising Organiz	ation:	Price Advertising	
Who Does What		Other Claims for Prescription Drugs	
Executive Summary	¶200	Promotion to Health Care Professionals	¶430
Office of the Commissioner		Educational and Scientific Events (Including	■ 12:
Center for Drug Evaluation and Research (CDE		CME)	
Center for Biologics Evaluation and Research	. "	Single-sponsor Publications	
(CBER)	¶230	Drug Detailing by Company Representatives	
Center for Devices and Radiological Health (CDI		Drug Sampling Exhibits and International Meetings	
Center for Food Safety and Applied Nutrition		Responding to Requests for Information	
(CFSAN)	¶250	Promoting to Formularies and Managed Care	430
Center for Veterinary Medicine (CVM)	¶260	Organizations	¶/2′
Center for Tobacco Products (CTP)	¶270	Organizations	43

<i>(ab 400 (cont d)</i>		CDRH's Policies for Monitoring Advertising and	
Use of Celebrities		Promotion of Devices	
Disclosing Payments to Physicians		Routine Submission of Materials to CDRH	
Direct-to-Consumer (DTC) Advertising		Preclearance of Promotional Materials	
Evolution of DTC Policy		Competitors' Complaints	
DTC Advertising in Print Media	¶442	Current Issues in FDA's Policies for Medical Devices	
DTC Advertising in Broadcast Media		Comparative Claims	
AMA Guidelines on DTC Advertising	¶444	Price Advertising/Pharmacoeconomics	¶622
Press Materials and Financial Communications	¶450	Investigational Device Advertising	¶623
Press Materials	¶451	Promotion of Pending 510(k) Devices	
Materials for the Financial Community	¶452	Promoting Unapproved Uses of Marketed Device	
Advertising Policies for Specific Types of Products	¶460	Direct-to-Consumer Promotion	¶626
Oral Contraceptives	¶461	FDA Policies for Specific Promotional Vehicles	¶630
Smoking Cessation Products	¶462	Educational and Scientific Events	
Cigarettes and Smokeless Tobacco	¶463	Public Relations Materials	¶632
Aerosol Steroid Safety Information	¶464	Investor Relations Materials	¶633
Ionic and Nonionic Contrast Agents	¶465	Single-sponsor Publications	¶634
Guidelines of Industry Organizations	¶470	Device Detailing by Company Representatives	¶635
PhRMA Code on Interactions with Health		Exhibits	
Care Professionals	¶471	Online Device Promotion	¶637
PhRMA Guiding Principles of DTC Advertisi	ng .¶472	Product Category Guidance	¶640
ABPI (U.K.) Code of Practice		In Vitro Diagnostic (IVD) Products	
Digital Health Coalition Guiding Principles	"	Guidelines of Industry Organizations	
for Social Media	¶474	AdvaMed's Code of Ethics on Interactions	
Online Drug Promotion		with Health Care Professionals	¶651
Responding to Off-label Requests Online		AdvaMed's Guiding Principles for DTC	
Interactive and Real-time Promotions		Device Advertising	¶652
Submitting Promotions for FDA Review		HIA's Code of Principles	
Draft Review Process		1	"
Formal Submission Process		Tab 700: Foods OTC Druge Nonroetri	ctod
		Tab 700: Foods, OTC Drugs, Nonrestri	Cleu
Tab 500: Biologics		Medical Devices and Cosmetics	
Tab 500: Biologics		Executive Summary	¶700
Executive Summary	¶500	FTC-FDA MOU for Food Advertising	
Historical Differences Between Policies for		and Labels	¶701
Drugs and Biologics	¶501	General Policies for Regulating Foods, OTC	
General Policies for Advertising and Promoting		Drugs, Non-restricted Devices and Cosmetics	
Biologics	¶510	Regulations Under the FTC Act	
Review of Materials by CBER	¶511	Advertising Agency Responsibility	
Approval Criteria for Biologics Advertising		Food Advertising Regulation	
and Promotion	¶512	Recent Cases and Activities	
Current Issues in Biologics Advertising and		Nutrition Labeling and Education Act (NLEA)	
Promotion	¶520	Lanham Act Liability	
CBER's Preclearance Policy	¶521	Dietary Supplement Advertising Regulation	
Comparative Advertising	¶522	FTC Policy	
Issuance of Press Releases and Other		FDA Policy	
Materials to Financial Community	¶523	Dietary Supplement Enforcement Activity	
Educational and Scientific Events for Biologic	cs¶524	OTC Drug Advertising Regulation by FTC	
Online Biologics Promotion		OTC Drug Advertising Policy	
-		Analgesics Advertising Policy	
Tab 600: Medical Devices		Aspercreme Case Study	
	 ¶€00	Diet Products and Programs	
Executive Summary	∏OUU	Industry's Code of Advertising Practices	
Difference Between Policies for Drugs and	T CO1	'White Coat' Rule	¶736
Devices	11		-
Checklist for Device Promotion	¶602		

Table of Contents

Medical Device Advertising Regulation. 9740 Nonrestricted Device Case Studies. 9741 Cosmetics Advertising Regulation. 9750 Cross-classification of Cosmetics. 1751 FDA and FTC Enforcement Standards. 9752 Tab 800: Veterinary Medicine Executive Summary. 9800 General Policies for Advertising and Promoting Veterinary Medicines. 9810 Educational and Scientific Events for Veterinary Medicines. 9820 BST Case Study of Advertising and Promoting Veterinary Medicines. 9820 BST Case Study of Advertising and Promoting Veterinary Medicines. 9820 BST Case Study. 9821 Tab 900: FDA Enforcement Executive Summary. 9900 The Basis for Increased FDA Enforcement. 9901 Notices of Violation (NOVs). 9911 Warning Letters for Prescription Drugs 1913 Criminal Prosecution. 9914 Remedies for Advertising and Promotion Violations. 920 Dar Health Care Provider Letters 1912 Corrective Advertising and Promotion 1940 Warning Letters for Prescription Drugs 9932 Other Letters for Prescription Drugs 9932 Other Letters for Prescription Drugs 9932 Alternerement of Medical Device Advertising and Promotion 1940 Warning Letters for Prescription Drugs 9932 Corporative Entry Agreements 9936 Marning Letters for Prescription Drugs 9937 The National Advertising Division 9930 Marning Letters and Safety Communications for Medical Device Advertising and Promotion 9940 Consent Davies and Safety Communications for Medical Device Advertising and Promotion 9940 Warning Letters for Prescription Drugs 9932 Corporative Entry Agreements 9933 Corporative Entry Agreements 9933 Corporative Entry Agreements 9934 Corporative Entry Agreements 9935 Corporative Entry Agreements 9936 Alternative Dispute Resolution 9930 The National Advertising Division 9930 The National Adve	<i>Tab 700 (cont'd)</i>	Appendix I: Federal Statutes and
Nonrestricted Device Case Studies 742 Restricted Device Case Studies 7742 Cosmetics Advertising Regulation 7750 Cross-classification of Cosmetics. 7751 FDA and FTC Enforcement Standards 7751 FDA and FTC Enforcement Standards 7752 Tab 800: Veterinary Medicine Executive Summary 7980 General Policies for Advertising and Promoting Veterinary Medicines 7981 Veterinary Medicines 7981 Educational and Scientific Events for 7981 Veterinary Medicines 7981 Listory of ISSEA (Including CME) 7981 Case Study Advertising and Promoting 7982 Veterinary Medicines 7982 BST Case Study 7982 BST Case Study 7982 Tab 900: FDA Enforcement 8982 BST Case Study 7982 Tab 900: FDA Enforcement 8982 BST Case Study 7982 Tab 900: FDA Enforcement 8992 The Basis for Increased FDA Enforcement 9902 The Basis for Increased FDA Enforcement 9902 The Basis for Increased FDA Enforcement 9902 The Standard 8992 Serizures and Injunctions 7993 Trade Associations Medical Groups Public Policy Organizations Related Materials Appendix II: Industry Standards For a detailed table of contents, see page 1 of specific appendix for a list structured by type. Prescription Drugs (Section A) Biologies (Section B) Medical Devices (Section D) General Material (Section E) Food (Section F) Volume II Appendix III: Industry Standards For a detailed table of contents, see page 1 of specific appendix for a list structured by type. Prescription Drug Stection A) Biologies (Section B) Wolume II Appendix II: Industry Standards For a detailed table of contents, see page 1 of specific appendix for a list structured by type. Prescription Drug Advertising appendix for a list structured by type. Prescription Drug Advertising and Promotion 9902 Poer Health Care Provider Letters 1991 Cornective Advertising and Promotion 1991 Warning Letters for Prescription Drugs 1993 Warning Letters for Prescription Dru	Medical Device Advertising Regulation	TE 40
Restricted Device Case Studies	Nonrestricted Device Case Studies	
Cosmetics Advertising Regulation. Cross-classification of Cosmetics. Tab 800: Veterinary Medicine Executive Summary. General Policies for Advertising and Promoting Veterinary Medicines. Selforcement Studding CME). Tab 900: FDA Enforcement Executive Summary Medicines. Selforcement Studding CME). Tab 900: FDA Enforcement Executive Summary. Selforcement Fools. Selforcement Gools. Selforcement Only Selforcement. Executive Summary. Selforcement Fools. Selforcement Fools. Selforcement Fools. Selforcement Fools. Selforcement of Prescription Drugs. Selforcement of Prescription Drugs. Selforcement of Medical Devices Companies. Enforcement Involving Judicial Action. Warning Letters for Prescription Drugs. Selforcement of Medical Devices Advertising and Promotion. Warning Letters for Prescription Drugs. Selforcement of Medical Devices. Selforcement Involving Judicial Action. Selforcements. Selforc	Restricted Device Case Studies	11/7/1/2)
Tab 800: Veterinary Medicine Executive Summary. Veterinary Medicines. Fistory of ISSEA (Including CME). Tab 900: FDA Enforcement Secondary Medicines. BST Case Study. Tab 900: FDA Enforcement Executive Summary. Tab 900: FDA Enforcement Executive Summary.	Cosmetics Advertising Regulation	[750
Tab 800: Veterinary Medicine Executive Summary	Cross-classification of Cosmetics	¶751
Executive Summary General Policies for Advertising and Promoting Veterinary Medicines. Educational and Scientific Events for Veterinary Medicines. History of ISSEA (Including CME). Case Study of Advertising and Promoting Veterinary Medicines. BST Case Study of Advertising and Promoting Veterinary Medicines. BST Case Study of Advertising and Promoting Veterinary Medicines. BST Case Study of Advertising and Promoting Veterinary Medicines. BST Case Study. BAPpendix III: Industry Standards For a detailed table of contents, see page 1 of specific appendix. BAPpendix IV: FDA Warning Letters to Drug Companies. BAPpendix IV:	FDA and FTC Enforcement Standards	
Executive Summary \$800 General Policies for Advertising and Promoting Veterinary Medicines \$810 Educational and Scientific Events for Veterinary Medicines \$810 History of ISSEA (Including CME) \$812 Case Study of Advertising and Promoting Veterinary Medicines \$820 BST Case Study of Advertising and Promoting Veterinary Medicines \$820 BST Case Study of Advertising and Promoting Veterinary Medicines \$820 BST Case Study of Advertising and Promoting Veterinary Medicine (Section D) General Material (Section E) Food (Section F) Volume II Appendix III: Industry Standards For a detailed table of contents, see page 1 of specific appendix. Trade Associations Related Materials Appendix IV: FDA Warning Letters Appendix IV: FDA Warning Letters To Drug Companies 2 Recent Warning Letters to Device Companies 2 Recent Warning Letters to Device Companies 2 Recent Untitled Letters to Biologics Companies		
Executive Summary General Policies for Advertising and Promoting Veterinary Medicines	Tab 800: Veterinary Medicine	
Prescription Drugs (Section A) Biologies (Section B)		structured by type.
Veterinary Medicines		
Educational and Scientific Events for Veterinary Medicines (Section C) Veterinary Medicines (Section D) (Section E) (Section E		
Veterinary Medicines \$811 History of ISSEA (Including CME) \$820 BST Case Study of Advertising and Promoting Veterinary Medicines \$820 BST Case Study of Advertising and Promoting Veterinary Medicines \$820 BST Case Study \$821 Tab 900: FDA Enforcement Executive Summary \$900 The Basis for Increased FDA Enforcement \$901 Responding to an Enforcement Action \$902 FDA's Enforcement Tools \$911 Warning Letters \$912 Seizures and Injunctions \$913 Criminal Prosecution \$914 Remedies for Advertising and Promotion Violations \$922 Toerrective Advertising and Promotion Violations \$923 Enforcement of Prescription Drug Advertising and Promotion Drugs \$933 Untitled Letters for Prescription Drugs \$933 Warning Letters for Prescription Drugs \$934 Enforcement of Biologics Advertising and Promotion \$944 Enforcement of Biologics Advertising and Promotion \$944 Enforcement of Biologics Advertising and Promotion \$944 Enforcement of Medical Device Advertising and Promotion \$944 Enforcement of Medical Device Advertising and Promotion \$944 Enforcement Involving Judicial Action \$961 Consent Decrees \$962 Corporate Integrity Agreements \$961 Consent Decrees \$962 Corporate Integrity Agreements \$961 Consent Agreements \$961 Consent Agreements \$962 Corporate Integrity Agreements \$961 Appendix II: Industry Standards \$600 (Section F) Volume II Appendix III: Industry Standards \$600 (Section S) \$		Biologics (Section B)
History of ISSEA (Including CME)		IIQ11
Case Study of Advertising and Promoting Veterinary Medicines		veter mary vieurine (Section D)
Veterinary Medicines		General Waterial (Section E)
Tab 900: FDA Enforcement Executive Summary 900 The Basis for Increased FDA Enforcement 901 Responding to an Enforcement Action 902 FDA's Enforcement Tools 911 Warning Letters 912 Seizures and Injunctions 913 Criminal Prosecution 914 Remedies for Advertising and Promotion Violations 920 Toear Health Care Provider' Letters 912 Instructions to Sales Representatives 923 Enforcement of Prescription Drug Advertising and Promotion 913 Warning Letters for Prescription Drugs 931 Warning Letters for Prescription Drugs 931 Warning Letters for Prescription Drugs 932 Cother Letters for Prescription Drugs 933 Enforcement of Biologics Advertising and Promotion 940 Warning Letters for Biologics 9941 Enforcement of Medical Device Advertising and Promotion 950 Warning Letters and Safety Communications for Medical Device Advertising and Promotion 950 Warning Letters and Safety Communications for Medical Devices 950 Consent Agreements 9951 Enforcement Involving Judicial Action 950 Alternative Dispute Resolution 970 The National Advertising 971 Health Claims Case Studies 971 Health Claims Case Studies 972 Cooperative Enforcement Activity 978		[820] Food (Section F)
Tab 900: FDA Enforcement Executive Summary		1821
Appendix III: Industry Standards The Basis for Increased FDA Enforcement. 901 Responding to an Enforcement Action. 9902 FDA's Enforcement Tools. 9910 Notices of Violation (NOVs). 9911 Warning Letters 9912 Seizures and Injunctions. 9913 Criminal Prosecution. 9914 Remedies for Advertising and Promotion Violations. 920 'Dear Health Care Provider' Letters 9921 Corrective Advertising 9922 Instructions to Sales Representatives 9923 Enforcement of Prescription Drug Advertising and Promotion. 9930 Untitled Letters for Prescription Drugs 9931 Warning Letters for Prescription Drugs 9931 Warning Letters for Prescription Drugs 9931 Enforcement of Biologics Advertising and Promotion 9940 Warning Letters for Biologics — 9941 Enforcement of Medical Device Advertising and Promotion 9950 Consent Agreements. 9961 Consent Agreements. 9962 Corporate Integrity Agreements. 9962 Corporate Integrity Agreements. 9963 Alternative Dispute Resolution 9970 The National Advertising Division 9971 Health Claims Case Studies 9972 Cooperative Enforcement Activity 990 Appendix III: Industry Standards For a detailed table of contents, see page 1 of specific appendix. Trade Associations Medical Groups Public Policy Organizations Related Materials Appendix IV: FDA Warning Letters Recent Warning Letters to Drug Companies 22 Recent Warning Letters to Device Companies 33 Recent Untitled Letters to Device Companies 34 Recent Untitled Letters to Drug Companies 35 Recent Untitled Letters to Biologics Companies 35 Recent Untitled Letters to Biologics Companies 31 Recent Untitled Letters to Drug Companies 32 Recent Untitled Letters to Drug Companies 34 Recent Untitled Letters to Drug Companies 35 Recent Untitled Letters to Drug Companies 34 Recent Untitled Letters to Biologics Companies 34 Recent Untitled Letters to Drug Companies 35 Recent Untitled Letters to Drug Companies 35 Recent Untitled Letters to Biologics Compani		Volume II
Appendix III: Industry Standards The Basis for Increased FDA Enforcement. 901 Responding to an Enforcement Action. 9902 FDA's Enforcement Tools. 9910 Notices of Violation (NOVs). 9911 Warning Letters 9912 Seizures and Injunctions. 9913 Criminal Prosecution. 9914 Remedies for Advertising and Promotion Violations. 920 'Dear Health Care Provider' Letters 9921 Corrective Advertising 9922 Instructions to Sales Representatives 9923 Enforcement of Prescription Drug Advertising and Promotion. 9930 Untitled Letters for Prescription Drugs 9931 Warning Letters for Prescription Drugs 9931 Warning Letters for Prescription Drugs 9931 Enforcement of Biologics Advertising and Promotion 9940 Warning Letters for Biologics — 9941 Enforcement of Medical Device Advertising and Promotion 9950 Consent Agreements. 9961 Consent Agreements. 9962 Corporate Integrity Agreements. 9962 Corporate Integrity Agreements. 9963 Alternative Dispute Resolution 9970 The National Advertising Division 9971 Health Claims Case Studies 9972 Cooperative Enforcement Activity 990 Appendix III: Industry Standards For a detailed table of contents, see page 1 of specific appendix. Trade Associations Medical Groups Public Policy Organizations Related Materials Appendix IV: FDA Warning Letters Recent Warning Letters to Drug Companies 22 Recent Warning Letters to Device Companies 33 Recent Untitled Letters to Device Companies 34 Recent Untitled Letters to Drug Companies 35 Recent Untitled Letters to Biologics Companies 35 Recent Untitled Letters to Biologics Companies 31 Recent Untitled Letters to Drug Companies 32 Recent Untitled Letters to Drug Companies 34 Recent Untitled Letters to Drug Companies 35 Recent Untitled Letters to Drug Companies 34 Recent Untitled Letters to Biologics Companies 34 Recent Untitled Letters to Drug Companies 35 Recent Untitled Letters to Drug Companies 35 Recent Untitled Letters to Biologics Compani	Tab 900: EDA Enforcement	
The Basis for Increased FDA Enforcement. 901 Responding to an Enforcement Action. 902 FDA's Enforcement Tools. 910 Notices of Violation (NOVs). 9011 Warning Letters. 9012 Seizures and Injunctions. 9102 Corrective Advertising and Promotion Violations. 920 Instructions to Sales Representatives. 921 Enforcement of Prescription Drug Advertising and Promotion. 930 Untitled Letters for Prescription Drugs. 931 Warning Letters for Prescription Drugs. 932 Other Letters for Prescription Drugs. 933 Enforcement of Biologics Advertising and Promotion 940 Warning Letters for Biologics — 941 Enforcement of Medical Device Advertising and Promotion 940 Warning Letters and Safety Communications for Medical Device Advertising and Promotion 950 Consent Agreements. 961 Consent Agreements. 961 Consent Agreements. 961 Consent Agreements. 963 Alternative Dispute Resolution 970 The National Advertising Division 971 Health Claims Case Studies 972 Cooperative Enforcement Activity 972 Cooperative Enforcement Activity 972 Cooperative Enforcement Activity 970 The National Advertising Division 970 Cooperative Enforcement Activity 970 The National Advertising Division 970 The National Advertising Division 970 The Rational Theorement Activity 970 The Rational Theorem 4		Appendix III: Industry Standards
Responding to an Enforcement Action		F 1 1 1 1 1 1 C 1 C
FDA's Enforcement Tools		1.
Notices of Violation (NOVs)		J
Naming Letters		16 11 16
Seizures and Injunctions		
Criminal Prosecution 914 Remedies for Advertising and Promotion Violations 920 'Dear Health Care Provider' Letters 921 Corrective Advertising 922 Instructions to Sales Representatives 923 Enforcement of Prescription Drug Advertising and Promotion 930 Untitled Letters for Prescription Drugs 931 Warning Letters for Prescription Drugs 932 Other Letters for Prescription Drugs 933 Enforcement of Biologics Advertising and Promotion 940 Warning Letters for Biologics 941 Enforcement of Medical Device Advertising and Promotion 950 Warning Letters and Safety Communications 960 Consent Agreements 961 Consent Decrees 962 Corporate Integrity Agreements 963 Alternative Dispute Resolution 970 The National Advertising Division 971 Health Claims Case Studies 972 Cooperative Enforcement Activity 980 Appendix IV: FDA Warning Letters Recent Warning Letters to Biologics Companies 2 Recent Warning Letters to Drug Companies 2 Recent Warning Letters to Drug Companies 3 Recent Warning Letters to Briologics Companies 2 Recent Warning Letters to Brug Companies 3 Recent Warning Letters to Brug Companies 3 Recent Warning Letters to Brug Companies 3 Recent Warning Letters to Brug Companie		
Appendix IV: FDA Warning Letters Packet Warning Letters to Drug Companies Packet Warning Letters to Biologics Companies Packet Warning Letters to Drug Companies Packet Warning Letters for Drug Companies Packet Warning Letters for Veterinary Medicines Packet Untitled Letters to Drug Companies Packet Untitled Letters to Biologics (Section Diversity Packet Untitled Letters to Biologics (Section Dive		
**Dear Health Care Provider' Letters		
Corrective Advertising		
Instructions to Sales Representatives 923 Enforcement of Prescription Drug Advertising and Promotion 930 Untitled Letters for Prescription Drugs 931 Warning Letters for Prescription Drugs 932 Other Letters for Prescription Drugs 933 Enforcement of Biologics Advertising and Promotion 940 Warning Letters for Biologics 9941 Enforcement of Medical Device Advertising and Promotion 950 Warning Letters and Safety Communications for Medical Devices 951 Enforcement Involving Judicial Action 960 Consent Agreements 961 Consent Decrees 962 Corporate Integrity Agreements 970 The National Advertising Division 971 Health Claims Case Studies 972 Cooperative Enforcement Activity 980 Recent Warning Letters to Device Companies and Distributors 38 Recent Warning Letters to Drug Companies 48 Recent Untitled Letters to Biologics Companies 12 Recent Untitled Letters to Drug Companies 58 Recent Untitled Letters to Drug Companies 12 Recent Untitled Letters to Drug Companies 1		
Enforcement of Prescription Drug Advertising and Promotion		
and Promotion		
Untitled Letters for Prescription Drugs		
Warning Letters for Prescription Drugs 932 Other Letters for Prescription Drugs 933 Enforcement of Biologics Advertising and Promotion 940 Warning Letters for Biologics 9941 Enforcement of Medical Device Advertising and Promotion 9550 Warning Letters and Safety Communications for Medical Devices 9551 Enforcement Involving Judicial Action 9560 Consent Agreements 9561 Consent Decrees 9562 Corporate Integrity Agreements 9570 The National Advertising Division 9570 Health Claims Case Studies 9580 Warning Letters to Biologics Companies 12 Recent Untitled Letters to Biologics Companies 12 Recent Advisory Action Letters to Veterinary Medicine Companies 13 Prescription Drugs (Section A) Biologics (Section B) Wedical Devices (Section C) Veterinary Medicine (Section E) Citizen's Petition (Section E) Appendix V: Consent Orders For a detailed table of contents, see page 1 of appendix. Appendix VI: FTC Releases and FYIs For a detailed table of contents, see page 1 of appendix.	·	
Other Letters for Prescription Drugs		
Enforcement of Biologics Advertising and Promotion Warning Letters for Biologics Enforcement of Medical Device Advertising and Promotion Warning Letters and Safety Communications for Medical Devices (Section B) Appendix V: Consent Orders For a detailed table of contents, see page 1 of appendix. Appendix VI: FTC Releases and FYIs For a detailed table of contents, see page 1 of appendix.		
Warning Letters for Biologics		
Enforcement of Medical Device Advertising and Promotion		
Promotion		
Warning Letters and Safety Communications for Medical Devices		
Enforcement Involving Judicial Action 960 Consent Agreements 9961 Consent Decrees 9962 Corporate Integrity Agreements 9963 Alternative Dispute Resolution 9770 The National Advertising Division 971 Health Claims Case Studies 972 Cooperative Enforcement Activity 980 Appendix V: Consent Orders For a detailed table of contents, see page 1 of appendix. Appendix VI: FTC Releases and FYIs For a detailed table of contents, see page 1 of appendix.		
Enforcement Involving Judicial Action	for Medical Devices	[951 Citizen's Petition (Section E)
Consent Decrees	Enforcement Involving Judicial Action	
Corporate Integrity Agreements 963 Alternative Dispute Resolution 970 The National Advertising Division 971 Health Claims Case Studies 980 Cooperative Enforcement Activity 980 The National Advertising Division 972 Cooperative Enforcement Activity 980 For a detailed table of contents, see page 1 of appendix. Appendix VI: FTC Releases and FYIs For a detailed table of contents, see page 1 of appendix.	Consent Agreements	961 Annendix V. Consent Orders
Corporate Integrity Agreements 963 Alternative Dispute Resolution 970 The National Advertising Division 971 Health Claims Case Studies 972 Cooperative Enforcement Activity 980 Corporate Integrity Agreements 963 Appendix VI: FTC Releases and FYIs For a detailed table of contents, see page 1 of appendix.	Consent Decrees	
The National Advertising Division	Corporate Integrity Agreements	1963
The National Advertising Division	Alternative Dispute Resolution	[970]
Health Claims Case Studies	The National Advertising Division	1971 Appendix VI: FIC Releases and FYIS
Cooperative Enforcement Activity¶980		
State Prosecution		¶980

[The next page is Current Contents, Page 19.]